Korean drug makers shy of M&A

Companies could benefit from mergers and acquisitions (M&As) in the changing business environment of the 21st century, but Korean drug firms are still showing a negative attitude towards M&As due to little synergistic effects and similar production structure among makers.

So far, Korean companies have been content to rely on generic drugs as their main source of income, and the ubiquitous pr...